Who are RENFLEXIS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Simponi, Cimzia, Enbrel, Remicade, CERTOLIZUMAB, YUSIMRY.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/infliximab-abda.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RENFLEXIS — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RENFLEXIS (INFLIXIMAB-ABDA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tumor Necrosis Factor Blocker [EPC]. Area: Other.

marketed Tumor Necrosis Factor Blocker [EPC] Other Live · refreshed every 30 min

Target snapshot

RENFLEXIS (INFLIXIMAB-ABDA) — SAMSUNG BIOEPIS CO LTD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RENFLEXIS TARGET	INFLIXIMAB-ABDA	SAMSUNG BIOEPIS CO LTD	marketed	Tumor Necrosis Factor Blocker [EPC]
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	marketed	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Enbrel	etanercept	Immunex	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Remicade	INFLIXIMAB	Johnson & Johnson	marketed	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
CERTOLIZUMAB	CERTOLIZUMAB		marketed	Tumor Necrosis Factor Blocker [EPC]
YUSIMRY	ADALIMUMAB-AQVH	COHERUS BIOSCIENCES INC	marketed	Tumor Necrosis Factor Blocker [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tumor Necrosis Factor Blocker [EPC] class)

SAMSUNG BIOEPIS CO LTD · 2 drugs in this class
COHERUS BIOSCIENCES INC · 1 drug in this class
Centocor Ortho Biotech Inc · 1 drug in this class
Immunex · 1 drug in this class
Johnson & Johnson · 1 drug in this class
SANDOZ INC · 1 drug in this class
· 1 drug in this class
UCB · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RENFLEXIS — Competitive Intelligence Brief. https://druglandscape.com/ci/infliximab-abda. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing